| Literature DB >> 22984598 |
Jeroen F J Bogie1, Silke Timmermans, Vân Anh Huynh-Thu, Alexandre Irrthum, Hubert J M Smeets, Jan-Åke Gustafsson, Knut R Steffensen, Monique Mulder, Piet Stinissen, Niels Hellings, Jerome J A Hendriks.
Abstract
Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system in which macrophages and microglia play a central role. Foamy macrophages and microglia, containing degenerated myelin, are abundantly found in active multiple sclerosis lesions. Recent studies have described an altered macrophage phenotype after myelin internalization. However, it is unclear by which mechanisms myelin affects the phenotype of macrophages and how this phenotype can influence lesion progression. Here we demonstrate, by using genome wide gene expression analysis, that myelin-phagocytosing macrophages have an enhanced expression of genes involved in migration, phagocytosis and inflammation. Interestingly, myelin internalization also induced the expression of genes involved in liver-X-receptor signaling and cholesterol efflux. In vitro validation shows that myelin-phagocytosing macrophages indeed have an increased capacity to dispose intracellular cholesterol. In addition, myelin suppresses the secretion of the pro-inflammatory mediator IL-6 by macrophages, which was mediated by activation of liver-X-receptor β. Our data show that myelin modulates the phenotype of macrophages by nuclear receptor activation, which may subsequently affect lesion progression in demyelinating diseases such as multiple sclerosis.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22984598 PMCID: PMC3440367 DOI: 10.1371/journal.pone.0044998
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Top 20 up- and downregulated genes in mye-macrophages.
| Affy ID | Gene name | Gene symbol | FC | P value |
|
| ||||
| 1368810_a_at | Myelin basic protein | MBP | 9.12 | 0.001 |
| 1367668_a_at | Stearoyl-CoA desaturase (delta-9-desaturase) | Scd | 4.02 | 0.027 |
| 1373098_at | Breast carcinoma amplified sequence 1 | BCAS1 | 3.81 | 0.007 |
| 1368103_at | ATP-binding cassette, sub-family G, member 1 | ABCG1 | 2.40 | 0.045 |
| 1375077_at | N/A | N/A | 1.77 | 0.009 |
| 1376652_at | Complement component 1, q subcomponent | C1qa | 1.75 | 0.039 |
| 1382153_at | C-type lectin, superfamily member 6 | Clescf6 | 1.64 | 0.046 |
| 1398262_at | Phosphoribosyl pyrophosphate synthetase 2 | Prps2 | 1.63 | 0.004 |
| 1391665_at | Fibroblast growth factor 7 | Fgf7 | 1.53 | 0.009 |
| 1382431_at | ATP-binding cassette, sub-family A, member 1 | ABCA1 | 1.52 | 0.023 |
| 1384534_at | GRAM domain containing 3 | GRAMD3 | 1.48 | 0.038 |
| 1380245_at | N/A | N/A | 1.45 | 0.024 |
| 1394673_at | Similar to Myeloid cell surface antigen CD33 | LOC687856 | 1.44 | 0.002 |
| 1370423_at | Guanine nucleotide binding protein, alpha 15 | GNA15 | 1.44 | 0.029 |
| 1373150_at | Catechol-O-methyltransferase domain containing 1 | COMTD1 | 1.44 | 0.036 |
| 1375932_at | Phosphoribosyl pyrophosphate synthetase 2 | Prps2 | 1.43 | 0.008 |
| 1372818_at | Collectin sub-family member 12 | Colec12 | 1.41 | 0.043 |
| 1376155_at | Family with sequence similarity 151, member B | FAM151B | 1.41 | 0.032 |
| 1374746_at | Ab1-152 | LOC500877 | 1.41 | 0.008 |
| 1390987_at | N/A | N/A | 1.40 | 0.021 |
|
| ||||
| 1392838_at | Similar to CG13957-PA | RGD1309995 | 0.47 | 0.016 |
| 1369067_at | Nuclear receptor subfamily 4, group A, member 3 | Nr4a3 | 0.47 | 0.009 |
| 1398846_at | Eukaryotic translation initiation factor 5 | EIF5 | 0.47 | 0.033 |
| 1394935_at | WAS protein family, member 2 | Wasf2 | 0.48 | 0.019 |
| 1369481_at | Tumor necrosis factor superfamily, member 4 | TNFSF4 | 0.49 | 0.042 |
| 1396225_at | Cytoplasmic polyadenylation binding protein 2 | CPEB2 | 0.49 | 0.011 |
| 1376739_at | DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 | DDX24 | 0.51 | 0.008 |
| 1395154_at | Zinc finger CCCH type containing 13 | ZC3H13 | 0.52 | 0.019 |
| 1380144_at | Mps One Binder kinase activator-like 1A/B (yeast) | MOBKL1A/B | 0.53 | 0.015 |
| 1395923_at | Nipped-B homolog (Drosophila) | Nipbl | 0.53 | 0.013 |
| 1395697_at | Enhancer of zeste homolog 2 (Drosophila) | Ezh2 | 0.54 | 0.029 |
| 1377151_at | N/A | N/A | 0.54 | 0.011 |
| 1381809_at | Ankyrin repeat domain 11 | Ankrd11 | 0.55 | 0.005 |
| 1387391_at | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | CDKN1A | 0.55 | 0.038 |
| 1391701_at | MYST histone acetyltransferase 3 | MYST3 | 0.55 | 0.013 |
| 1375453_at | Hypothetical protein LOC688211 | LOC688211 | 0.56 | 0.006 |
| 1398217_at | Zinc finger and BTB domain containing 41 | Zbtb41 | 0.56 | 0.033 |
| 1380446_at | Myeloid/lymphoid or mixed-lineage leukemia 10 | Mllt10 | 0.56 | 0.005 |
| 1381993_at | Chloride intracellular channel 2 | CLIC2 | 0.57 | 0.026 |
| 1374594_at | Similar to RIKEN cDNA 1600029D21 | LOC363060 | 0.57 | 0.035 |
Overrepresented canonical pathways and biological functions (IPA).
| Downregulated gene pool | Upregulated gene pool |
|
| |
| p53 Signaling | Aminosugars Metabolism |
| mTOR Signaling | Thyroid Cancer Signaling |
| Growth Hormone Signaling | PPAR Signaling |
| Cell Cycle: G2/M DNA Damage Regulation | Relaxin Signaling |
| CNTF Signaling | Complement System |
| Nur77 Signaling in T Lymphocytes | LXR/RXR Activation |
| FLT3 Signaling in Hematopoietic Progenitor Cells | cAMP-mediated Signaling |
| RhoA Signaling | |
| Interleukin-8 Signaling | |
| Regulation of eIF4 and p70S6K Signaling | |
| ATM Signaling | |
|
| |
| Cellular Development | Carbohydrate Metabolism |
| Gene Expression | Amino Acid Metabolism |
| Cell-To-Cell Signaling and Interaction | Cellular Compromise |
| Cellular Growth and Proliferation | Gene Expression |
| Cellular Function and Maintenance | Nucleic Acid Metabolism |
| Protein Synthesis | Small Molecule Biochemistry |
| Cell Morphology | Cell Cycle |
| Cell Cycle | Cell Signaling |
| Cellular Assembly and Organization | Lipid Metabolism |
| DNA Replication, Recombination, and Repair | Molecular Transport |
| Cellular Compromise | Antigen Presentation |
| Amino Acid Metabolism | Cell-To-Cell Signaling and Interaction |
| Post-Translational Modification | Cellular Assembly and Organization |
| Small Molecule Biochemistry | Cellular Growth and Proliferation |
| Cell Death | DNA Replication, Recombination, and Repair |
| Antigen Presentation | Cellular Development |
| Carbohydrate Metabolism | Cellular Function and Maintenance |
| Lipid Metabolism | Cell Morphology |
| Cell Signaling | Cell Death |
| Nucleic Acid Metabolism | |
| Cellular Movement |
Figure 1Quantitative PCR validation.
Comparison of fold changes between IFNγ/IL1β-stimulated untreated (n = 5) and myelin treated macrophages (n = 5). Relative quantification of gene expression (SCD1/2, ABCA1/G1 and RXRα/β/γ) was accomplished by using the comparative Ct method. Data were normalized to the most stable reference genes, determined by Genorm (18S and PGK1).
Figure 2Mye-macrophages have an increased capacity to transfer intracellular cholesterol towards HDL.
Macrophages were loaded for 48 hours with 1,2- [3H] cholesterol after which cells were treated with myelin for 24 hours or left untreated. HDL was used as cholesterol acceptor. The relative cholesterol efflux is defined as the amount of transported cholesterol in culture medium of mye-macrophages divided by values in control macrophage cultures. Data represent the mean of four independent experiments.
Figure 3Myelin and T0901317 affect the expression of LXR response genes in a similar manner.
(a–c) Comparison of fold changes of LXR response genes between untreated (dotted line) and myelin- or T0901317-treated macrophages. Macrophages were treated for 24 and 48 hours with 100 µg/ml myelin or 10 µM T0901317 after which expression of ApoE and ABCA1/G1 was determined. Relative quantification of gene expression was accomplished by using the comparative Ct method. Data were normalized to the most stable reference genes, determined by Genorm (18S and PGK-1). Data represent the mean of four independent experiments. (d) Comparison of fold changes of ABCA1 between untreated (dotted line) and myelin treated wild-type, LXRα-, LXRβ- and LXRαβ-deficient mouse macrophages. Macrophages were treated 48 hours with 100 µg/ml myelin. Data were normalized to the most stable reference genes, determined by Genorm (CycA and HMBS). Data represent the mean of four independent experiments. Mye; Myelin: T09; T0901317.
Figure 4Myelin alters the macrophage phenotype by activating the LXRβ isoform.
(a–d) Relative NO and IL-6 concentration in supernatants of IFNγ/IL-1β or LPS stimulated myelin- or T0901317-treated macrophages. The relative NO and IL-6 production is defined as the production of NO/IL-6 in experimental cultures divided by values in stimulated control cultures (dotted line). Data represent the mean of four independent experiments. (e, f) Relative NO and IL-6 concentration in supernatants of LPS stimulated myelin treated wild-type, LXRα-, LXRβ- and LXRαβ-deficient mouse macrophages. Macrophages were treated for 24 hours with myelin prior to stimulation with LPS. Data represent the mean of four independent experiments. Mye; Myelin: T09; T0901317.